Page 2 - John Rossmeisl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Scientists from Virginia Tech, City of Hope aim to improve therapy for deadly brain cancer Published Sunday, May. 9, 2021, 11:15 am Join AFP's 100,000+ followers on Facebook Purchase a subscription to AFP Subscribe to AFP podcasts on iTunes and Spotify News, press releases, letters to the editor: augustafreepress2@gmail.com (© sdecoret – stock.adobe.com) Glioblastoma multiforme is among the most lethal of cancers and the most stubborn in the face of treatment. Fewer than 20 percent of patients survive more than two years after diagnosis, according to the Central Brain Tumor Registry of t...

Researchers receive $3.75 million to study the impact of fluid flow on CAR-T cell therapy for brain cancer Glioblastoma multiforme is among the most lethal of cancers and the most stubborn in the face of treatment. Fewer than 20 percent of patients survive more than two years after diagnosis, according to the Central Brain Tumor Registry of the United States. But a team of researchers at Fralin Biomedical Research Institute at VTC and City of Hope, a comprehensive care center, believes the complex way fluid flows through glioblastoma tumors holds the key to the therapy's success. They believe...

 E-Mail IMAGE: Jennifer Munson and her lab at the Fralin Biomedical Research Institute at VTC will build tissue-engineered model tumors to test how fluid flow can be manipulated to improve CAR-T cell... view more  Credit: Clayton Metz/Virginia Tech Glioblastoma multiforme is among the most lethal of cancers and the most stubborn in the face of treatment. Fewer than 20 percent of patients survive more than two years after diagnosis, according to the Central Brain Tumor Registry of the United States. But a team of researchers at Fralin Biomedical Research Institute at VTC and City of ...